• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Press release

Genovis AB: Genovis Launches FabRICATOR® Xtra: Next-Generation Enzyme for Future Antibody Therapeutics

Genovis

Genovis AB, a leading provider of innovative enzyme technologies, announce the launch of FabRICATOR® Xtra, the second generation of its widely used FabRICATOR (IdeS) enzyme. This newly developed enzyme is specifically designed to address the evolving needs of biopharmaceutical development by efficiently digesting next-generation antibody-based therapeutics with mutations designed to enhance their therapeutic properties.

New generations of antibody-based therapeutics, designed with structural mutations, have posed a challenge to traditional enzyme technologies. These therapeutic antibodies, while offering enhanced efficacy and stability, could not be digested with legacy FabRICATOR® (IdeS), preventing researchers from utilizing the efficient middle-level workflows previously enabled by the enzyme.

FabRICATOR® Xtra is an innovative solution to this challenge. With its ability to precisely and efficiently digest novel engineered antibody formats, Genovis is once again advancing analytical workflows for developers of future therapeutics antibodies. The new enzyme offers the same high level of accuracy and speed that users have come to expect from FabRICATOR®, ensuring that it can seamlessly integrate into existing workflows while supporting the development of future antibody-based therapies.

"With FabRICATOR® Xtra, we're excited to offer a solution to our customers working at the forefront of antibody-based therapeutic innovation. Our next-generation enzyme supports more complex and mutated antibody formats, giving researchers the tools they need to continue developing the therapies of tomorrow", said Fredrik Olsson, CEO at Genovis.

FabRICATOR® Xtra builds upon the success of its predecessor by maintaining the same precision, accuracy, and efficiency, while extending its utility to novel formats. Genovis remains committed to supporting the biopharmaceutical industry with innovative, high-performance tools that address the demands of modern therapeutic development.

For more information on FabRICATOR® Xtra please visit: https://www.genovis.com/smartenzymes/antibody-digestion/fabricator-xtra/